It is now well accepted that many tumors undergo a process of clonal selection which means
that tumor antigens arising at various stages of tumor progression are likely to be …

The immunotherapeutic treatment of various cancers with an increasing number of immune
checkpoint inhibitors (ICIs) has profoundly improved the clinical management of advanced …

Background: The latest immunotherapy, used in the treatment of non-small cell lung cancer
(NSCLC), uses monoclonal antibodies directed against programmed death ligand 1 (PD-L1) …

Close proximity between cytotoxic T lymphocytes and tumour cells is required for effective
immunotherapy. However, what controls the spatial distribution of T cells in the tumour …

T cell-mediated immune therapies have emerged as a promising treatment modality in
different malignancies including colorectal cancer (CRC). However, only a fraction of …

The treatment landscape for patients with advanced non-small cell lung cancer has evolved
greatly with the advent of immune checkpoint inhibitors. However, many patients do not …

Background Limited data exist on the role of alterations in HLA Class I antigen processing
and presentation machinery in mediating response to immune checkpoint blockade (ICB) …

Lung cancer remains a leading cause of cancer death worldwide, with non-small-cell lung
cancer (NSCLC) accounting for the majority of cases. Immune checkpoint inhibitors (CPIs) …

Major histocompatibility complex (MHC) class I antigen presentation deficiency is a common
cancer immune escape mechanism, but the mechanistic implications and potential …

Background We aimed to assess the impact of genomic human leukocyte antigen (HLA)-I/II
homozygosity on the survival benefit of patients with unresectable locally advanced …